Physician profile
Holly E Rooney
NPI 1194738674
$1,443.95
in general payments reported to CMS, 2019-2025
23 companies · $307 in 2025
The $307 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2020: $118 · 2021: $72.76 · 2022: $168 · 2023: $436 · 2024: $124 · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $848 · Entertainment: $18.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $848.32 |
| Entertainment | $18.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $433.47 | 2023-2025 | Aveir, Gallant, Assurity |
| Novo Nordisk INC | $236.65 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.56 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $87.88 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $74.10 | 2019-2020 | |
| Abbvie INC. | $47.00 | 2023 | Qulipta, Ubrelvy, Vraylar |
| Novartis Pharmaceuticals Corporation | $42.69 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $37.53 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $32.78 | 2019-2023 | Xtampza |
| Nestle Healthcare Nutrition INC. | $27.72 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.72 | 2021-2022 | |
| Astellas Pharma US INC | $25.20 | 2024 | Veozah |
| Phathom Pharmaceuticals, INC. | $25.19 | 2025 | Voquezna |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.90 | 2023 | Lifevest |
| Exact Sciences Corporation | $18.65 | 2025 | Cologuard Collection Kit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $18.28 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Dexcom, INC. | $17.49 | 2025 | Dexcom G6 Transmitter |
| Grifols USA, LLC | $15.93 | 2019 | |
| Aimmune Therapeutics, INC. | $15.13 | 2024 | |
| Merck Sharp & Dohme LLC | $14.43 | 2019 | |
| Corcept Therapeutics | $14.39 | 2025 | Korlym |
| Glaxosmithkline, LLC. | $13.25 | 2020 | |
| Travere Therapeutics, INC. | $2.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Rooney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.